glyburide has been researched along with 2019 Novel Coronavirus Disease in 2 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "SARS-CoV-2 infection and linked cytokine storm may cause blood-brain barrier (BBB) injury through which activated immune cells and SARS-CoV-2 can pass into the brain causing activation of glial cells with subsequent neuroinflammation." | 3.01 | Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal. ( Al-Gareeb, AI; Al-Kuraishy, HM; Albogami, SM; Alorabi, M; Alruwaili, M; AlRuwaili, R; Batiha, GE; Saad, HM; Simal-Gandara, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batiha, GE | 3 |
| Al-Kuraishy, HM | 3 |
| Al-Gareeb, AI | 3 |
| Alruwaili, M | 3 |
| AlRuwaili, R | 3 |
| Albogami, SM | 3 |
| Alorabi, M | 3 |
| Saad, HM | 3 |
| Simal-Gandara, J | 3 |
| Ferraz, WR | 1 |
| Gomes, RA | 1 |
| S Novaes, AL | 1 |
| Goulart Trossini, GH | 1 |
1 review available for glyburide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
Topics: COVID-19; Cytokine Release Syndrome; Glyburide; Humans; Inflammasomes; Neuroinflammatory Diseases; N | 2023 |
1 other study available for glyburide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an
Topics: Antiviral Agents; Betacoronavirus; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cyste | 2020 |